Denali Therapeutics initiates coverage with Overweight rating and $35 target price
DNLI•Wells Fargo initiated coverage of Denali Therapeutics with an Overweight rating and a $35 target price.
Related News
Eos Energy director Alexander Dimitrief reports acquisition of $46,500 in common shares
EOSE•
Siebert Financial sees diesel costs sustaining inflation despite falling oil prices
SIEB•
Press digest-Canada - November 13
RY•
Edgewell Personal Care Company: Wells Fargo raises target price to $32 from $30
EPC•
Cisco Systems: Wells Fargo cuts target price to $130 from $150
CSCO•